CSPC Pharmaceutical Group (01093) has announced that its long-acting injection of a GLP-1/GIP receptor dual-biased agonistic polypeptide (SYH2082 injection) has received approval from China's National Medical Products Administration to commence clinical trials in China. SYH2082 had also previously received approval from the U.S. Food and Drug Administration (FDA) in February 2026 to conduct clinical trials in the United States. SYH2082 has the potential to become a leading long-acting GLP-1/GIP receptor dual-biased agonist in the clinical development stage, administered once monthly. Leveraging the group's long-acting formulation technology platform, SYH2082 enables monthly dosing, improving patient compliance and convenience of use. SYH2082 selectively activates the cAMP pathway and reduces β-arrestin recruitment, thereby minimizing receptor internalization and desensitization, which enhances efficacy and prolongs the duration of action. Furthermore, SYH2082 incorporates both a long half-life modification platform technology and a long-acting formulation platform technology, designed to achieve sustained weight reduction throughout the dosing interval. In preclinical studies, SYH2082 demonstrated superior efficacy compared to similar marketed products in terms of long-term weight loss and weight maintenance, supporting a once-monthly dosing regimen. In toxicology studies, SYH2082 was well-tolerated with no significant adverse effects observed. The approved clinical indication is for weight management in individuals with obesity or overweight who have at least one weight-related comorbidity. Additionally, SYH2082 has the potential to improve glycemic control in adults with type 2 diabetes, offering further clinical benefits. The approval for clinical trials represents a significant achievement for the group in its strategic layout of innovative long-acting products in the metabolic disease field and lays a solid foundation for the development of more innovative products in the future.